Krishidhan Seeds Limited

Belkins
Our R&D activities and research centers are recognized by the Department of Scientific and Industrial Research (DSIR), Govt. of India. We see ourselves emerging as one of the biggest technology driven Indian agricultural input company with a significant global presence, providing access to latest technologies and all required quality agricultural inputs for the socio economic growth of farmers worldwide.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BIOCARE MEDICAL AND BETHYL LABORATORIES ANNOUNCES THE RELEASE OF A NEW RABBIT MONOCLONAL ANTIBODY FOR IMMUNOHISTOCHEMICAL APPLICATIONS

Biocare Medical | August 05, 2020

news image

Biocare Medical LLC, a leading provider of innovative, automated immunohistochemistry (IHC) reagents and instrumentation, in collaboration with Bethyl Laboratories announces the release of a new rabbit monoclonal antibody, TIGIT [BLR047F] antibody for in vitro diagnostic (IVD) use in the qualitative identification of the TIGIT protein by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human tissues.TIGIT plays an important role in transplantation tolerance and tumor i...

Read More

CELL AND GENE THERAPY

BRAZIL’S SENAI CIMATEC DOSES FIRST HEALTHY VOLUNTEERS IN PHASE 1 TRIAL OF HDT BIO’S RNA COVID-19 VACCINE

HDT Bio Corp. | January 17, 2022

news image

HDT Bio Corp., a U.S. developer of immunotherapies for oncology and infectious diseases and SENAI CIMATEC, an important Brazilian education, research, and innovation institute, have dosed the first healthy volunteers in Brazil in a Phase 1 trial of HDT Bio’s RNA COVID-19 vaccine, HDT-301. SENAI CIMATEC will conduct the clinical trial under the name Vaccine RNA MCTI-CIMATEC-HDT. The vaccine uses HDT Bio’s proprietary lipid nanoparticle RNA-delivery technology. Read More

CELL AND GENE THERAPY

IMARA ANNOUNCES PRIMARY ENDPOINT CHANGE IN THE ARDENT PHASE 2B CLINICAL TRIAL OF TOVINONTRINE (IMR-687) IN SICKLE CELL DISEASE

Imara | November 22, 2021

news image

Imara Inc. a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today announced a change to the primary endpoint for the Ardent clinical trial, a Phase 2b study of tovinontrine (IMR-687) in patients with sickle cell disease (SCD), based on the recommendation of the U.S. Food and Drug Administration (FDA). Imara requested f...

Read More

MEDICAL

GT BIOPHARMA ANNOUNCES FDA DATA - GTB-3550, FOR TREATMENT OF HIGH-RISK MYELODYSPLASTIC SYNDROMES

GT Biopharma | December 23, 2020

news image

GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology organization focused in on innovative treatments dependent on the Company's restrictive NK cell engager (TriKE™) innovation stage is satisfied to report the introduction of extra interval information results for the Company's lead therapeutic competitor, GTB-3550, for the treatment of high-risk myelodysplastic syndromes (HR-MDS). Erica Warlick, M.D, Principal Investigator for the GTB-3550 clinical trial, i...

Read More
news image

BIOCARE MEDICAL AND BETHYL LABORATORIES ANNOUNCES THE RELEASE OF A NEW RABBIT MONOCLONAL ANTIBODY FOR IMMUNOHISTOCHEMICAL APPLICATIONS

Biocare Medical | August 05, 2020

Biocare Medical LLC, a leading provider of innovative, automated immunohistochemistry (IHC) reagents and instrumentation, in collaboration with Bethyl Laboratories announces the release of a new rabbit monoclonal antibody, TIGIT [BLR047F] antibody for in vitro diagnostic (IVD) use in the qualitative identification of the TIGIT protein by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human tissues.TIGIT plays an important role in transplantation tolerance and tumor i...

Read More
news image

CELL AND GENE THERAPY

BRAZIL’S SENAI CIMATEC DOSES FIRST HEALTHY VOLUNTEERS IN PHASE 1 TRIAL OF HDT BIO’S RNA COVID-19 VACCINE

HDT Bio Corp. | January 17, 2022

HDT Bio Corp., a U.S. developer of immunotherapies for oncology and infectious diseases and SENAI CIMATEC, an important Brazilian education, research, and innovation institute, have dosed the first healthy volunteers in Brazil in a Phase 1 trial of HDT Bio’s RNA COVID-19 vaccine, HDT-301. SENAI CIMATEC will conduct the clinical trial under the name Vaccine RNA MCTI-CIMATEC-HDT. The vaccine uses HDT Bio’s proprietary lipid nanoparticle RNA-delivery technology. Read More

news image

CELL AND GENE THERAPY

IMARA ANNOUNCES PRIMARY ENDPOINT CHANGE IN THE ARDENT PHASE 2B CLINICAL TRIAL OF TOVINONTRINE (IMR-687) IN SICKLE CELL DISEASE

Imara | November 22, 2021

Imara Inc. a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today announced a change to the primary endpoint for the Ardent clinical trial, a Phase 2b study of tovinontrine (IMR-687) in patients with sickle cell disease (SCD), based on the recommendation of the U.S. Food and Drug Administration (FDA). Imara requested f...

Read More
news image

MEDICAL

GT BIOPHARMA ANNOUNCES FDA DATA - GTB-3550, FOR TREATMENT OF HIGH-RISK MYELODYSPLASTIC SYNDROMES

GT Biopharma | December 23, 2020

GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology organization focused in on innovative treatments dependent on the Company's restrictive NK cell engager (TriKE™) innovation stage is satisfied to report the introduction of extra interval information results for the Company's lead therapeutic competitor, GTB-3550, for the treatment of high-risk myelodysplastic syndromes (HR-MDS). Erica Warlick, M.D, Principal Investigator for the GTB-3550 clinical trial, i...

Read More